Anthony Bunn
Corporate Secretary at De Novo Pharmaceuticals Ltd.
Network origin in Anthony Bunn first degree
Entity | Entity type | Industry | |
---|---|---|---|
De Novo Pharmaceuticals Ltd.
De Novo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology De Novo Pharmaceuticals Ltd. discovers and develops drugs. It is a novel molecular structure generating drug discovery platform targeting pathogenic bacteria. The firm offers lower cost, rapid, lower molecular weights hits, novel, and patentable hit molecules. The company was founded by David Bailey, Iwan de Esch, and Philip Dean M on April 28, 1999 and is headquartered in London, the United Kingdom.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Anthony Bunn via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Organon BioSciences NV
Organon BioSciences NV Pharmaceuticals: MajorHealth Technology Organon Biosciences NV specializes in biopharmaceutical manufacturing and distribution services. It develops products in the areas of cardiovascular disease, fertility, gynecology, anesthesia, respiratory, consumer health care, and neuroscience, immunology, animal health, and oncology. The company’s products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, cold/flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. It was founded in 1923 and is headquartered in Oss, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Aventis, Inc. | Corporate Officer/Principal | ||
Tibotec Virco NV
Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Concept Life Sciences Integrated Discovery & Dev Services Ltd.
Concept Life Sciences Integrated Discovery & Dev Services Ltd. Pharmaceuticals: MajorHealth Technology Concept Life Sciences Integrated Discovery & Dev Services Ltd. designs, produces and supplies novel compounds. It offers a range of products and services to its pharmaceutical and biotechnology customers to accelerate drug discovery initiatives. The company was founded by Ray Fisher on February 9, 1989 and is headquartered in High Peak, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Roche Corp. | Corporate Officer/Principal | ||
University of Cambridge | College/University | Doctorate Degree | |
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Medical Distributors | Chief Executive Officer | |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Biotechnology | Chief Executive Officer | |
Hercules Pharmaceuticals BV
Hercules Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Hercules Pharmaceuticals BV operates as biopharmaceutical company, which develops oral and non-toxic drug therapy for chronic treatment of patients with triple negative breast cancer. The company was founded by David Sherr in 2013 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer | |
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Medical Specialties | Chief Executive Officer | |
LanthioPep BV
LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Medical Specialties | Chief Executive Officer | |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | President | |
MEDIVIR AB | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
Netherlands | 6 |
United Kingdom | 6 |
United States | 4 |
Sweden | 4 |
Belgium | 3 |
Sectoral
Health Technology | 11 |
Commercial Services | 4 |
Consumer Services | 2 |
Distribution Services | 2 |
Finance | 2 |
Operational
Corporate Officer/Principal | 12 |
Chief Executive Officer | 5 |
Director/Board Member | 3 |
President | 2 |
Founder | 1 |
Most connected contacts
Insiders | |
---|---|
Per Källblad | 11 |
Bart Wuurman | 9 |
Amit Agarwal | 1 |
Frederick Farhad Fahid | 1 |
- Stock Market
- Insiders
- Anthony Bunn
- Company connections